Use of a marketing plan for recruitment to a lung cancer screening study.

Authors

null

John R. Goffin

Juravinski Cancer Centre, Burlington, ON, Canada

John R. Goffin , Gregory Russell Pond , Alain Tremblay , Michael R. Johnston , Glenwood D. Goss , Garth Andrew Nicholas , Simon Martel , Rick Bhatia , Geoffrey Liu , Heidi Roberts , Martin Tammemagi , Sukhinder Atkar-Khattra , Ming Sound Tsao , Stephen C. Lam , Janice Rudkowski

Organizations

Juravinski Cancer Centre, Burlington, ON, Canada, Ontario Clinical Oncology Group, Hamilton, ON, Canada, Division of Respiratory Medicine, University of Calgary and Alberta Thoracic Oncology Program, Calgary, AB, Canada, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada, Ottawa Hospital Research Institute, Ottawa, ON, Canada, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC, Canada, Memorial University, St. John's, NF, Canada, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Hospital, Toronto, ON, Canada, Brock University, Hamilton, ON, Canada, The British Columbia Cancer Agency, Vancouver, BC, Canada, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, Ryerson University, Toronto, ON, Canada

Research Funding

Other

Background: Recruitment to clinic trials is typically poor. Among barriers to recruitment may be the limited knowledge of trialists with respect to marketing techniques. Improvements in marketing could decrease recruitment time and shorten the time to access new interventions. We hypothesized that a marketing plan would improve recruitment to a lung cancer screening study. Methods: The Pan-Canadian Early Detection of Lung Cancer Trial recruited subjects from 8 centres to a screening study of low-dose CT scan and autofluorescence bronchoscopy. Recruitment processes were undertaken independently at each centre. One centre (M) used marketing expertise and a marketing plan, including surveying study candidates for motivators, resulting in specific newsprint advertisements. Screened trial candidates provided demographic and tobacco use data and indicated how they had heard about the study (bus, friend/family, MD, mail, newsprint, radio, TV, other). No site paid for radio or TV time. We used regression analyses to assess whether newsprint advertisements were more effective for recruitment at site M compared with all other sites. Results: From 2008 to 2010, 7059 candidates contacted all centres for eligibility screening, including 779 at centre M. Overall, 50.2% were female; median age was 59 yrs. Compared with other centres, candidates at centre M had less education (p < 0.001), a higher median 3-year lung cancer risk (2.3 vs 2.0%, p < 0.001), but were more likely to have learned of the study by newsprint (58.8 vs 53.3%, chi-squared p = 0.004), and were more likely to be recruited (44.0 vs 34.9%, p < 0.001). It was more likely that newsprint was the driver for screening contact among candidates with higher education level (OR 1.05/level), higher age (OR 1.03 / yr) and contact at site M (OR 1.31) (all < 0.001). Recruitment after eligibility screening was higher when newsprint was the driver for contact on univariable but not multivariable analysis. Conclusions: The effectiveness of newsprint advertising in motivating study contact may be improved by the formal use of marketing expertise. Newsprint advertising may improve the likelihood of recruitment after study screening, possibly through improved initial self-screening by the candidate. Clinical trial information: NCT00751660

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Cancer Prevention, Genetics, and Epidemiology

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Cancer Prevention

Clinical Trial Registration Number

NCT00751660

Citation

J Clin Oncol 35, 2017 (suppl; abstr 1548)

DOI

10.1200/JCO.2017.35.15_suppl.1548

Abstract #

1548

Poster Bd #

206

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

Rates of colorectal cancer screening versus lung cancer screening: Where does the problem lie?

First Author: Sasmith R. Menakuru

Abstract

2023 ASCO Annual Meeting

Lung cancer screening status and acceptability of a personalized approach in Texas.

First Author: Paul Resong

Abstract

2022 ASCO Annual Meeting

Screening for high frequency malignant disease (SHIELD).

First Author: HA NGUYEN

First Author: Sasmith R. Menakuru